inner-banner

TARGET PPP

ANZICS CTG Endorsed Study

TARGET PPP

TARGET point prevalence study

Study Description

The Augmented versus Routine approach to Giving Energy Trial (TARGET) was a 4000-patient randomised controlled, multicentre trial comparing augmented enteral energy delivery to standard care on 90-day survival. TARGET completed recruitment in November 2017. In order to evaluate the influence TARGET has had on current practice and may have on future practice, an understanding of current nutrition practices in Australian and New Zealand intensive care units (ICUs) must be obtained. Data on protein prescription will also guide a Phase III trial on protein delivery in critically ill adults.

This is a prospective, observational, multicentre, single-day, point-prevalence study. The objective is to determine common nutrition (energy and protein) prescriptions across Australia and New Zealand ICUs.

Management Committee

Anneleen Neuts (PI), Lee-anne Chapple (PI), Andrew Davies, Professor Marianne Chapman, Donna Goldsmith, Sue Huckson, Lorraine Little (Project Manager), John L Moran, Stephanie O’Connor (Project Manager), Sandra Peake, and Patricia Williams.

Administering Institution

Central Adelaide Local Health Network

Collaborators

This study will be conducted in collaboration with the TARGET Investigator Group.

Sample Size

All adult patients (≥16 years of age) present in participating ICUs at 10:00 AM on the study day will be enrolled. Based on the number of participating sites (28 in Australia and 11 in New Zealand) we would anticipate that 500-600 patients will be included.

Funding

Per patient payments and CORE database set-up costs will be provided from the TARGET program grant (NHMRC: ClinicalTrials.gov NCT02306746, APP1078026, >$3.5m, 2015-19, CIA-Chapman).

Project Status as of June 2018

Ethics: Ethics approval is nearly completed for all sites. 2 countries and 4 jurisdictions / HREC applications – New Zealand (as a TARGET protocol amendment), RAH (lead Australian site) and Tasmania (RHH complete, Launceston underway); plus one private hospital submission in WA (non NMA).

Governance: Australia: 20 sites RGO approval complete; two sites have not submitted but plan to submit as soon as possible; 6 sites pending approval.

Data collection: Will be conducted retrospectively by sites as ethics and governance approvals are obtained.

Data analysis and manuscript preparation: To commence once data entry is complete.

Reference

CTG1718-09

Contact

Lee-anne Chapple (email)